Publication Name	World Journal of Gastroenterology
Manuscript ID	4027
Country	South Korea

Received	2013-06-13 12:04
Peer-Review Started	2013-06-14 08:54
To Make the First Decision	2013-06-24 10:28
Return for Revision	2013-07-01 13:28
Revised	2013-08-11 16:40
Second Decision	2013-09-17 09:39
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-09-17 11:01
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor	2013-11-02 19:59
Typeset the Manuscript	2013-11-26 10:13
Publish the Manuscript Online	2013-12-18 09:53

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Autobiography
Article Title	Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir
Manuscript Source	Invited Manuscript
All Author List	Hana Park, Jun Yong Park, Seung Up Kim, Do Young Kim, Kwang-Hyub Han, Chae Yoon Chon and Sang Hoon Ahn
Funding Agency and Grant Number	Funding Agency Grant Number Liver Cirrhosis Clinical Research Center, a grant from the Korea Healthcare Technology R and D project, Ministry of Health and Welfare, South Korea HI10C2020 Bilateral International Collaborative R and D Program from the Ministry of Trade, Industry and Energy, South Korea
Corresponding Author	Sang Hoon Ahn, MD, PhD, Department of Internal Medicine, Yonsei University College of Medicine, 150 Shinchon-dong 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, South Korea. ahnsh@yuhs.ac
Key Words	Chronic hepatitis B; Antiviral resistance; Suboptimal response; Telbivudine; Lamivudine
Core Tip	A suboptimal response is common in patients treated with lamivudine (LAM) + adefovir (ADV) combination therapy and it has also become a new challenge for the management of chronic hepatitis B (CHB) patients. We commenced this study with the effect of telbivudine (LdT) + ADV combination therapy as a rescue therapeutic option in LAM-resistant CHB patients with suboptimal response to LAM + ADV. Our results demonstrated that switching from LAM + ADV to LdT + ADV resulted in superior virologic response, renoprotective effect and similar safety profiles at week 48. These results suggest that LdT + ADV could be a therapeutic option for patients who are unable to use enofovir disoproxil fumarate for any reason.
Publish Date	2013-12-18 09:53
Citation	Park H, Park JY, Kim SU, Kim DY, Han KH, Chon CY, Ahn SH. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. World J Gastroenterol 2013; 19(43): 7671-7679
URL	http://www.wjgnet.com/1007-9327/full/v19/i43/7671.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i43.7671

Full Article (PDF)	WJG-19-7671.pdf
Manuscript File	4027-Review.doc
Answering Reviewers	4027-Answering reviewers.pdf
Copyright License Agreement	4027-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	4027-Language certificate.pdf
Peer-review Report	4027-Peer review(s).pdf
Scientific Editor Work List	4027-Scientific editor work list.doc